Single blind randomized controlled clinical study to evaluate the efficacy and safety of shivagutika in dyslipidemia

Rajiv Gandhi University of Health Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients fulfilling the diagnostic criteria.
•2.Lipid profile, showing any one or more of the following criteria.
•Serum cholesterol >200 mg/dl
•Serum Triglycerides >150 mg/dl
•Serum LDL >130 mg/dl
•Serum VLDL >40 mg/dl
•Serum HDL <40 for male <30 for female
•Ratio of HDL to Cholesterol >4.5
•Apolipoprotien B >125mg/dl
•3.Both fresh and treated cases will be included (Flush out period of 7 days is maintained for treated cases)

•1.Patients having history of serious cardiac disorders like myocardial infarction, cardiac failure, etc.
•2.Patients having any major illness, insulin dependent diabetes mellitus, Type II diabetes mellitus that is poorly controlled
•3.Patients having a history of untreated thyroid disorder
•4.Hyperlipidemia due to drugs (e.g., glucocorticoids)
•5.Pregnant females and lactating mothers
•6.Renal insufficiency

发起方